Study S000799

Effect of LY2189265 on the Pharmacokinetics of Atorvastatin in Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01250834
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 27
Start: 2010-12
Primary completion: 2011-03
Lead sponsor: Eli Lilly and Company
Conditions: Healthy Volunteers
Interventions: DRUG:Atorvastatin; BIOLOGICAL:LY2189265
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBCP; EUDRACT_NUMBER:2010-021657-39

Registered primary outcomes

Pharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax) [Pre-dose to 56 hours post-dose]
Pharmacokinetics of Atorvastatin: Area Under the Curve (AUC) [Pre-dose to 56 hours post-dose]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011520	No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide. de la Peña A, Clinical pharmacokinetics	2017	Other trial	PMID 28357715 DOI	cites ClinicalTrials.gov:NCT01250834; registry reference DERIVED:28357715